share_log

Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics

Benzinga ·  Aug 8 10:31

Cantor Fitzgerald analyst Eric Schmidt reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment